Tag: executive

WINNIPEG, Manitoba, June 13, 2025 (GLOBE NEWSWIRE) -- (TSX Symbol: NWC): The North West Company Inc. (the “Company” or “North West”) today announced that shareholders voted in favour of all items of business put forth by the Company at its annual general meeting of shareholders held on June 11, 2025, including the election of all the nominee directors listed in the Notice of Meeting and Management Information Circular dated April 9, 2025:

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that dosing has commenced at the prestigious Weill Cornell Medicine Multiple Sclerosis Center in New York City, in its ongoing Phase 2 clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This fifth site complements existing sites at Yale University, Johns Hopkins University, Brigham and Women's Hospital, and the University of Massachusetts.

Digital Advertising Sales Leader, Nico Greco, Promoted to Chief Revenue Officer, North America

VANCOUVER, British Columbia, June 13, 2025 (GLOBE NEWSWIRE) -- 1317229 B.C. Ltd. (“131” or the “Company”) and Launchit Solutions Inc. (“Launchit”) are pleased to announce that the Company, Launchit and 1001240330 Ontario Inc. (“Subco”), a wholly-owned subsidiary of the Company, have entered into a business combination agreement dated June 12, 2025 (the “Business Combination Agreement”) pursuant to which the Company will acquire Launchit by way of a three-cornered amalgamation, which will result in the reverse takeover of 131 by Launchit (the “Proposed Transaction”). Upon completion of the Proposed Transaction, the Company will continue to carry on the business of Launchit (thereafter referred to as the “Resulting Issuer”).

SAN FRANCISCO, CALIFORNIA, June 13, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE^® natural killer (NK) cell engager platform, today announced the appointment of David C. Mun-Gavin to its Board of Directors.

Millicom (Tigo) Announces Partial Closing of Infrastructure Deal with SBA and Intention to Declare a Special Dividend of $2.50 per Share Representing Around 45% of the Proceeds